$ALKS

Gaffin David Joseph sold $110K of ALKS

Gaffin David Joseph (EVP, CLO, Alkermes, Inc.) sold 2,034 shares of Alkermes plc. (ALKS) at $54.03 ($0.11M total) on 2026-07-06 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Gaffin David Joseph
Published Jul 6, 2026, 8:48 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 6, 2026, 9:04 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ALKS
Neutral
high confidence
Mentioned
$ALKS
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ALKSNeutralLow
01

Why it matters

The newest disclosed fact is the same-day open-market sale of 2,034 shares by an EVP at a stated price, under a pre-arranged 10b5-1 plan.

02

Market read

Traders may note the insider sale for sentiment monitoring, but there is no new fundamental information to drive a directional trade.

03

What to watch

The article lacks context on total planned sales, prior insider activity cadence, and whether the sale was part of a larger scheduled program; without that, signal strength is limited.

Relevance 3/10Novelty 3/10Timing: Filed on 2026-07-06 (after-hours) for an insider sale executed the same day.

Background

This is a SEC Form 4 insider transaction filed via EDGAR for Alkermes plc (ALKS).

Company-level read

Ticker impact

$ALKSNeutralHigh confidence
Context

Alkermes EVP David Joseph Gaffin filed a Form 4 selling 2,034 shares at $54.03 on 2026-07-06 under a 10b5-1 plan.

Expected impact

Low likelihood of sustained price impact; any reaction is likely muted and short-lived.

Evidence & confidence

The filing is an open-market sale by an officer, explicitly under a pre-arranged 10b5-1 plan, with no accompanying operational, financial, or regulatory news disclosed.

Market effects

No clear read-across to the biotech/pharma sector because the disclosure is a planned insider transaction without new company fundamentals.

Minimal; this is a single-company insider sale with no broader market linkage stated.

Low; no international deal, regulator action, or supply-chain event is mentioned.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can still be watched as a sentiment check, especially if it coincides with other negative signals not present here.

Key entities

  • Alkermes plc

    Subject of the Form 4 insider transaction; EVP David Joseph Gaffin sold shares under a 10b5-1 plan.

  • David Joseph Gaffin

    EVP, CLO at Alkermes; reported open-market sale of 2,034 shares at $54.03.

Related articles

$ALKSMed

Alkermes plc Q2 2026 Earnings Call Summary

Strategic Evolution and Operational Context Management characterized the current period as a major phase of growth, with the orexin platform evolving from a hypersomnolence focus to a broad neurocircuitry platform for ADHD and fatigue. Alixorexton is positioned as a leading asset, being the only orexin 2 receptor agonist to demonstrate efficacy and tolerability across both NT1 and NT2 in large Phase 2 studies.

$ALKSMedAI 8/10

Alkermes plc. (ALKS): Results of Operations and Financial Condition

Alkermes plc. (ALKS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 alks-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Alkermes Contacts: For Investors: Sandy Coombs +1 781 609 6377 For Media: Katie Joyce +1 781 249 8927 Alkermes plc Reports Second Quarter 2026 Financial Results — Second Quarter Revenues of $496.0 Million — — GAAP Net Income

$ALKSMed

Interim Analysis: Sustained Wakefulness with Alixorexton in Narcolepsy

Alkermes plc reported interim results from a long-term extension study of alixorexton in adults with narcolepsy type 1 and type 2. At week 24, alixorexton showed sustained improvements on the Maintenance of Wakefulness Test and Epworth Sleepiness Scale, with mean MWT sleep latency about 29 minutes (NT1) and 18 minutes (NT2) and mean ESS about 7.5 (NT1) and 8.9 (NT2). No serious treatment-emergent adverse events were reported.

$ALKSMed

First MS Mobility Drug Gets Green Light From NHS England

NHS England said it will make fampridine (Fampyra), a pill for adults with multiple sclerosis-related walking impairment, routinely available on the NHS after a Clinical Priorities Advisory Group review. NHSE cited trials showing improved walking speed in 43% of patients and about a 25% speed increase, with ~5,000 eligible patients in England in year one. The decision follows a 2022 NICE cost-effectiveness refusal and the expiry of the Fampyra brand patent.